SCHEMBL2913642

SCHEMBL2913642

c1ccc(-c2nc(-c3ccccn3)nc3ccccc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 5/20 0.64
MAPT P10636 4/20 0.57
ALDH1A1 P00352 2/20 0.57
POLB P06746 1/20 0.57
KMT2A Q03164 6/20 0.55
MEN1 O00255 4/20 0.55
ATM Q13315 1/20 0.55
RAB9A P51151 4/20 0.55
TDP1 Q9NUW8 4/20 0.55
KDM4E B2RXH2 1/20 0.55
L3MBTL1 Q9Y468 4/20 0.54
MAPK1 P28482 3/20 0.54
NPC1 O15118 2/20 0.54
LMNA P02545 2/20 0.54
TSHR P16473 2/20 0.54
ADORA3 P0DMS8 1/20 0.54
PPP1CA P62136 2/20 0.52
AGTR1 P30556 1/20 0.52
PDE5A O76074 1/20 0.52
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24590225 0.95 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL23996434 0.92 METAP1 (0.59) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589753 0.92 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589752 0.91 METAP1 (0.57) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589747 0.88 METAP1 (0.57) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL16436774 0.87 KMT2A (0.60) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589846 0.87 KMT2A (0.54) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24590229 0.85 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL25460394 0.85 KMT2A (0.51) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589754 0.85 KMT2A (0.57) METAP1MAPTALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110606839-B Green synthesis method of polysubstituted quinazoline derivative 南方医科大学 2021-10-08 CN claimed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
EP-1966184-B1 PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-08-25 EP disclosed
US-20090306102-A1 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2009-12-10 US disclosed
EP-1966184-A2 PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2008-09-10 EP disclosed
WO-2007071632-A2 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D METAP1 1610/4885MAPT 20/4885ALDH1A1 2638/4885
US-20090306102-A1 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES KCNJ2, KCNQ1, KCNK2 METAP1 4254/4885MAPT 2920/4885ALDH1A1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.